SCHEMBL10149196

SCHEMBL10149196

CN1C(=O)C(c2ccc3ccccc3c2)N=C(c2ccc(O)cc2)c2cc(Cl)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 3/20 0.57
LMNA P02545 2/20 0.57
PDE3A Q14432 1/20 0.57
PDE4D Q08499 2/20 0.49
HTR2B P41595 1/20 0.49
CHRM2 P08172 1/20 0.48
ADRA2A P08913 1/20 0.48
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
CACNA1F O60840 1/20 0.43
ALB P02768 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
AKR1C3 P42330 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29544459 0.82 OPRK1 (0.54) OPRK1LMNAPDE3APDE4DHTR2B
SCHEMBL1687457 0.82 OPRK1 (0.54) OPRK1LMNAPDE3APDE4DHTR2B
SCHEMBL29410184 0.82 OPRK1 (0.54) OPRK1LMNAPDE3APDE4DHTR2B
SCHEMBL10149194 0.80 OPRK1 (0.56) OPRK1LMNAPDE3APDE4DHTR2B
SCHEMBL14536845 0.80 OPRK1 (0.59) OPRK1LMNAPDE3APDE4DHTR2B
SCHEMBL9059928 0.79 OPRK1 (0.62) OPRK1LMNAPDE3APDE4DHTR2B
SCHEMBL6124997 0.78 LMNA (0.55) OPRK1LMNAPDE4DALBCCKBR
SCHEMBL10193351 0.77 OPRK1 (0.60) OPRK1LMNAPDE3APDE4DHTR2B
SCHEMBL11964613 0.76 OPRK1 (0.62) OPRK1LMNAPDE3APDE4DHTR2B
SCHEMBL10149097 0.75 LMNA (0.49) OPRK1LMNAPDE3APDE4DHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2062583-B1 Therapeutic applications of pro-apoptotic benzodiazepines UNIV MICHIGAN (US) 2012-12-26 EP disclosed
EP-2422788-A2 Benzodiazepines and compositions and uses thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-02-29 EP disclosed
EP-2359831-A2 Therapeutic applications of pro-apoptotic benzodiazepines The Regents of the University of Michigan (US) 2011-08-24 EP disclosed
US-20090012065-A1 Therapeutic applications of pro-apoptotic benzodiazepines NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-01-08 US disclosed
US-7220739-B2 Therapeutic application of pro-apoptotic benzodiazepines REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-05-22 US disclosed
WO-2007053193-A2 UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-05-10 WO disclosed
US-20070036854-A1 Therapeutic applications of pro-apoptotic benzodiazepines NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012065-A1 Therapeutic applications of pro-apoptotic benzodiazepines BAD, GABRB1, GABRA5 OPRK1 40/4885LMNA 143/4885PDE3A 1765/4885
US-20070036854-A1 Therapeutic applications of pro-apoptotic benzodiazepines BAD, GABRB1, GABRA5 OPRK1 40/4885LMNA 143/4885PDE3A 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.